Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,exchangeDataDelayedBy,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,country,website,maxAge,address1,industry,address2
t0,GANX,44464009.0,11876600,1421509,,-2446968,,-2450447,1050675,0,-2466915,-2466915,-5269,,,,,3479,0,2466915,0,19947,,-2450447,-2450447,54104982.0,3577055.0,44464009.0,188138.0,48041064.0,1188.0,11129.0,-9485300.0,194465.0,-156861.0,103302.0,46593604.0,2326737.0,44287.0,-156861.0,553734.0,47384028.0,71452.0,678255.0,881753.0,21862.0,-28488.0,41990305.0,14832.0,42629998.0,39132006.0,-19904.0,-2809907.0,40703.0,-513738.0,-639693.0,73425.0,-28488.0,,45057291.0,en-US,US,EQUITY,True,Delayed Quote,7.83,1630526403,0.029999733,7.8,8.099,7.75,42558,-5.3265305,8.37075,-0.5407505,-0.064600006,10.45193,-2.6219301,-0.25085607,92993776,15,America/New_York,EDT,False,False,USD,-1.47,us_market,"Gain Therapeutics, Inc.",NGM,POST,2,0.38461196,7.75 - 8.099,7.8,7.83,8.0,9,22,finmb_554488027,NasdaqGM,"Gain Therapeutics, Inc.",USD,26926,18900,0.32999992,0.04399999,7.5 - 17.93,-10.1,-0.56330174,7.5,17.93,0,-14400000,,,,17.93,7.5,8.37,10.45,26.93k,18.9k,11.88M,,8.76M,34.60%,8.34%,44.08k,1.48,0.41%,0.37%,4.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-5.42M,-5.44M,,,46.59M,3.92,1.22M,2.75,20.36,,-5.3M,,Value,20814,Healthcare,11,"Gain Therapeutics, Inc., a development stage biotechnology company, engages in developing various therapeutics to treat diseases caused by protein misfolding. It focuses rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, treating the underlying disease. It is developing structurally targeted allosteric regulator candidates in various preclinical studies to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.",Bethesda,301-500-1556,MD,United States,http://www.gaintherapeutics.com,86400,4800 Hampden Lane,Biotechnology,Suite 200
t-1,GANX,6201517.0,11876600,975612,,-1657049,,-1655681,649162,0,-1615635,-1615635,-9139,,,,,-1368,0,1615635,0,-41414,,-1655681,-1655681,13388666.0,3402369.0,6201517.0,245860.0,9604358.0,402.0,1439020.0,-7034853.0,171558.0,-152698.0,63817.0,7492910.0,2114831.0,22626.0,-152698.0,552713.0,8987828.0,55898.0,715656.0,961516.0,231988.0,-14551.0,-440347.0,39060.0,42629998.0,-1774759.0,-11644.0,-1308217.0,120421.0,-6687.0,-481298.0,-31452.0,-14551.0,30396.0,6872997.0,en-US,US,EQUITY,True,Delayed Quote,7.83,1630526403,0.029999733,7.8,8.099,7.75,42558,-5.3265305,8.37075,-0.5407505,-0.064600006,10.45193,-2.6219301,-0.25085607,92993776,15,America/New_York,EDT,False,False,USD,-1.47,us_market,"Gain Therapeutics, Inc.",NGM,POST,2,0.38461196,7.75 - 8.099,7.8,7.83,8.0,9,22,finmb_554488027,NasdaqGM,"Gain Therapeutics, Inc.",USD,26926,18900,0.32999992,0.04399999,7.5 - 17.93,-10.1,-0.56330174,7.5,17.93,0,-14400000,,,,17.93,7.5,8.37,10.45,26.93k,18.9k,11.88M,,8.76M,34.60%,8.34%,44.08k,1.48,0.41%,0.37%,4.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-5.42M,-5.44M,,,46.59M,3.92,1.22M,2.75,20.36,,-5.3M,,Value,20814,Healthcare,11,"Gain Therapeutics, Inc., a development stage biotechnology company, engages in developing various therapeutics to treat diseases caused by protein misfolding. It focuses rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, treating the underlying disease. It is developing structurally targeted allosteric regulator candidates in various preclinical studies to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.",Bethesda,301-500-1556,MD,United States,http://www.gaintherapeutics.com,86400,4800 Hampden Lane,Biotechnology,Suite 200
t-2,GANX,-449955.0,11876600,417259,,-582921,,-584268,101674,0,-512260,-512260,-6673,-1747.0,,,,1347,0,512260,0,-70661,,-584268,-584268,,,-449955.0,,,,,,,,,,,,,,,,,,-239326.0,-4897.0,1392695.0,8085.0,42629998.0,631409.0,-3573.0,-752816.0,26345.0,62947.0,-481298.0,-24244.0,-4897.0,284598.0,,en-US,US,EQUITY,True,Delayed Quote,7.83,1630526403,0.029999733,7.8,8.099,7.75,42558,-5.3265305,8.37075,-0.5407505,-0.064600006,10.45193,-2.6219301,-0.25085607,92993776,15,America/New_York,EDT,False,False,USD,-1.47,us_market,"Gain Therapeutics, Inc.",NGM,POST,2,0.38461196,7.75 - 8.099,7.8,7.83,8.0,9,22,finmb_554488027,NasdaqGM,"Gain Therapeutics, Inc.",USD,26926,18900,0.32999992,0.04399999,7.5 - 17.93,-10.1,-0.56330174,7.5,17.93,0,-14400000,,,,17.93,7.5,8.37,10.45,26.93k,18.9k,11.88M,,8.76M,34.60%,8.34%,44.08k,1.48,0.41%,0.37%,4.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-5.42M,-5.44M,,,46.59M,3.92,1.22M,2.75,20.36,,-5.3M,,Value,20814,Healthcare,11,"Gain Therapeutics, Inc., a development stage biotechnology company, engages in developing various therapeutics to treat diseases caused by protein misfolding. It focuses rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, treating the underlying disease. It is developing structurally targeted allosteric regulator candidates in various preclinical studies to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.",Bethesda,301-500-1556,MD,United States,http://www.gaintherapeutics.com,86400,4800 Hampden Lane,Biotechnology,Suite 200
t-3,GANX,-449955.0,11876600,482179,,-707799,,-709576,221633,0,-694885,-694885,-8927,-1008.0,,,,1777,0,694885,0,-12914,,-709576,-709576,3088154.0,1110142.0,-449955.0,372499.0,660286.0,225.0,81290.0,-3457171.0,132247.0,-81163.0,11413.0,303320.0,879052.0,,-81163.0,219348.0,429525.0,44915.0,,154441.0,299598.0,-7147.0,1392695.0,62873.0,42629998.0,-339954.0,8907.0,-341714.0,98515.0,-1574.0,-20610.0,-89915.0,-7147.0,284598.0,-449527.0,en-US,US,EQUITY,True,Delayed Quote,7.83,1630526403,0.029999733,7.8,8.099,7.75,42558,-5.3265305,8.37075,-0.5407505,-0.064600006,10.45193,-2.6219301,-0.25085607,92993776,15,America/New_York,EDT,False,False,USD,-1.47,us_market,"Gain Therapeutics, Inc.",NGM,POST,2,0.38461196,7.75 - 8.099,7.8,7.83,8.0,9,22,finmb_554488027,NasdaqGM,"Gain Therapeutics, Inc.",USD,26926,18900,0.32999992,0.04399999,7.5 - 17.93,-10.1,-0.56330174,7.5,17.93,0,-14400000,,,,17.93,7.5,8.37,10.45,26.93k,18.9k,11.88M,,8.76M,34.60%,8.34%,44.08k,1.48,0.41%,0.37%,4.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-5.42M,-5.44M,,,46.59M,3.92,1.22M,2.75,20.36,,-5.3M,,Value,20814,Healthcare,11,"Gain Therapeutics, Inc., a development stage biotechnology company, engages in developing various therapeutics to treat diseases caused by protein misfolding. It focuses rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, treating the underlying disease. It is developing structurally targeted allosteric regulator candidates in various preclinical studies to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.",Bethesda,301-500-1556,MD,United States,http://www.gaintherapeutics.com,86400,4800 Hampden Lane,Biotechnology,Suite 200
